$JAZZ Jazz Pharmaceuticals plc Insider Trading Week 10/2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Jazz Pharmaceuticals plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Jazz Pharmaceuticals plc in week 10/2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP & General Couns ... | Payment of Exercise | F | 132.81 | 2,087 | 277,174 | 42,149 | 44.2 K to 42.1 K (-4.72 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Option Exercise | M | 59.13 | 750 | 44,348 | 0 | |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Option Exercise | M | 46.83 | 2,896 | 135,620 | 0 | |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Buy | M | 59.13 | 750 | 44,348 | 22,408 | 21.7 K to 22.4 K (+3.46 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Buy | M | 46.83 | 2,896 | 135,620 | 21,658 | 18.8 K to 21.7 K (+15.44 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Payment of Exercise | F | 132.81 | 563 | 74,772 | 18,762 | 19.3 K to 18.8 K (-2.91 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | Treacy Paul | SVP, Technical Oper ... | Sell | S | 131.98 | 529 | 69,815 | 17,579 | 18.1 K to 17.6 K (-2.92 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | Treacy Paul | SVP, Technical Oper ... | Sell | S | 131.98 | 355 | 46,851 | 18,108 | 18.5 K to 18.1 K (-1.92 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | McGill Iain | SVP, Europe & Rest ... | Payment of Exercise | F | 132.81 | 818 | 108,639 | 20,383 | 21.2 K to 20.4 K (-3.86 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman & CEO | Payment of Exercise | F | 132.81 | 5,000 | 664,050 | 309,491 | 314.5 K to 309.5 K (-1.59 %) |
| Mar 08 2017 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & COO | Payment of Exercise | F | 132.81 | 1,793 | 238,128 | 52,795 | 54.6 K to 52.8 K (-3.28 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP & General Couns ... | Option Exercise | A | 136.18 | 24,266 | 3,304,544 | 24,266 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP & General Couns ... | Option Exercise | A | 136.18 | 734 | 99,956 | 734 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Hooper Suzanne Sawochka | EVP & General Couns ... | Grant | A | 0.00 | 10,000 | 0 | 44,236 | 34.2 K to 44.2 K (+29.21 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Young Matthew P. | EVP & CFO | Option Exercise | A | 136.18 | 24,266 | 3,304,544 | 24,266 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Young Matthew P. | EVP & CFO | Option Exercise | A | 136.18 | 734 | 99,956 | 734 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Young Matthew P. | EVP & CFO | Grant | A | 0.00 | 10,000 | 0 | 41,913 | 31.9 K to 41.9 K (+31.34 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Option Exercise | A | 136.18 | 7,781 | 1,059,617 | 7,781 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Option Exercise | A | 136.18 | 969 | 131,958 | 969 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | WILSON KAREN J | SVP, Finance & PAO | Grant | A | 0.00 | 3,500 | 0 | 19,325 | 15.8 K to 19.3 K (+22.12 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Treacy Paul | SVP, Technical Oper ... | Option Exercise | A | 136.18 | 11,250 | 1,532,025 | 11,250 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Treacy Paul | SVP, Technical Oper ... | Grant | A | 0.00 | 4,500 | 0 | 18,463 | 14 K to 18.5 K (+32.23 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 136.18 | 17,848 | 2,430,541 | 17,848 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Option Exercise | A | 136.18 | 902 | 122,834 | 902 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Smith Karen L. | Global Head of R&D ... | Grant | A | 0.00 | 7,500 | 0 | 21,168 | 13.7 K to 21.2 K (+54.87 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | MILLER MICHAEL PATRICK | SVP, US Commercial | Option Exercise | A | 136.18 | 17,848 | 2,430,541 | 17,848 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | MILLER MICHAEL PATRICK | SVP, US Commercial | Option Exercise | A | 136.18 | 902 | 122,834 | 902 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | MILLER MICHAEL PATRICK | SVP, US Commercial | Grant | A | 0.00 | 7,500 | 0 | 22,962 | 15.5 K to 23 K (+48.51 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | McGill Iain | SVP, Europe & Rest ... | Option Exercise | A | 136.18 | 11,250 | 1,532,025 | 11,250 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | McGill Iain | SVP, Europe & Rest ... | Grant | A | 0.00 | 4,500 | 0 | 21,201 | 16.7 K to 21.2 K (+26.94 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman & CEO | Option Exercise | A | 136.18 | 85,766 | 11,679,614 | 85,766 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman & CEO | Option Exercise | A | 136.18 | 734 | 99,956 | 734 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | COZADD BRUCE C | Chairman & CEO | Grant | A | 0.00 | 34,600 | 0 | 314,491 | 279.9 K to 314.5 K (+12.36 %) |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & COO | Option Exercise | A | 136.18 | 24,266 | 3,304,544 | 24,266 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & COO | Option Exercise | A | 136.18 | 734 | 99,956 | 734 | |
| Mar 06 2017 | JAZZ | Jazz Pharmaceutica ... | Cox Russell J. | EVP & COO | Grant | A | 0.00 | 10,000 | 0 | 54,588 | 44.6 K to 54.6 K (+22.43 %) |